We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy

EP38573
Abstract: The development of ADCs has been accelerated worldwide in recent years, and this novel biotechnological drug is a potent anticancer agent and also considered an essential disease treatment. The complex structure and a high degree of heterogeneity of ADC pose significant challenges for structural characterization. Among them, the determination of the drug-to-antibody ratio (DAR), drug conjugation site, and conjugation ratio are relatively complicated. BOC Sciences' ADC solution platform will help you solve these problems and challenges.Summary: BOC Sciences provides comprehensive strategies for antibody-drug conjugate (ADC) to our customers worldwide. We possess the most advanced equipment and unique R&D expertise to provide personalized antibody coupling services according to customers' specific needs promptly. Moreover, we monitor our products according to strict quality control standards during development and optimization processes to ensure our customers receive first-class services and products.References: https://adc.bocsci.com/services/antibody-modification-and-conjugation-technologies.html
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Related Posters
Development of QSP model of COVID-19 based on Immune Response Template
Veronika Musatova, Oleg Demin, Maria Kupriyanova, Anna Viktorenko
Future Perspective of PROTAC Combined With CRISPR In Anti-ancer Area
Sunny Fang
Top 10 Most Popular Pharmaceutical Research Areas: Market Landscape
Sunny Fang
5 Potential Applications of mRNA Therapy
Sunny Fang
ADC Drugs Global Sales of 2021 and Future Prospects
Sunny Fang